The CryoCord Group’s patented technologies, listed below, represent key contributions that have been formally recognised and protected through national and international patent grants.
| No. | Company | Patented Country | Patent Code | Title |
|---|---|---|---|---|
| 1 | Cytopeutics | United States | US 10,278,993 B2 | CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF ACUTE STROKE |
| 2 | Cytopeutics | United States | US 10,828,332 B2 | CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF VERNAL KERATOCONJUNCTIVITIS |
| 3 | Cytopeutics | United States | US 11,052,119 B2 | CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF DIABETES AND ASSOCIATED METABOLIC DISORDERS AND FOR AMELIORATION OF INSULIN RESISTANCE IN PRE-DIABETES |
| 4 | CryoCord | Malaysia | MY-196334-A | A METHOD FOR SCREENING BIOLOGICAL SPECIMEN AND MESENCHYMAL STEM CELL OR MULTIPOTENT STROMAL CELLS TO ESTABLISH MASTER CELL LINE |
| 5 | CryoCord | Malaysia | MY-198403-A | PRODUCTION OF THERAPEUTICS POTENTIAL MESENCHYMAL STEM CELLS |
| 6 | Cytopeutics | Malaysia | MY-171193-A | A CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF DIABETES AND ASSOCIATED METABOLIC DISORDERS AND FOR AMELIORATION OF INSULIN RESISTANCE IN PRE-DIABETES |
| 7 | Cytopeutics | Malaysia | MY-173966-A | A CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF ACUTE STROKE |
| 8 | Cytopeutics | Malaysia | MY-176109-A | A CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF CRITICAL LIMB ISCHEMIA |
| 9 | Cytopeutics | Malaysia | MY-171690-A | A CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF END-STAGE ISCHEMIC CARDIOMYOPATHY |
| 10 | Cytopeutics | Malaysia | MY-171311-A | A CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF DIABETIC MACULAR OEDEMA |
| 11 | Cytopeutics | Malaysia | MY-173386-A | A CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF VERNAL KERATOCONJUNCTIVITIS |
| 12 | Cytopeutics | Malaysia | MY-176088-A | CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF PSORIASIS AND AUTOIMMUNE DISEASES |
| 13 | Cytopeutics | Malaysia | MY-200544-A | A METHOD OF EXPANDING AND GENERATING A POPULATION OF CYTOKINE-INDUCED KILLER CELLS FROM PERIPHERAL BLOOD |
| 14 | Cytopeutics | Malaysia | MY-206887-A | A CELL-BASED COMPOSITION AND USE THEREOF FOR TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE |
Remarks: Cytopeutics is a subsidiary of the CryoCord Group, primarily focused on stem cell research and treatment.